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MethylationLong-lived postmitotic cells, such as most human neurons, must respond effectively to ongoing changes in
neuronal stimulation or microenvironmental cues through transcriptional and epigenomic regulation of
gene expression. The role of epigenomic regulation in neuronal function is of fundamental interest to the
neuroscience community, as these types of studies have transformed our understanding of gene regulation
in postmitotic cells. This perspective article highlights many of the resources available to researchers inter-
ested in neuroepigenomic investigations and discusses some of the current obstacles and opportunities in
neuroepigenomics.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).Neuroepigenomics comes of age
Epigenetic changes are historically deﬁned as heritable changes
that alter transcription but not the underlying DNA sequence. Unlike
cells in many other tissues, most neurons in the human brain are
postmitotic (Gage and Temple, 2013; Lacar et al., 2014), with many
individual neurons appearing to survive and function for decades.
Thus, gene expression and associated synaptic changes are required
to effectively respond to altered neuronal inputs, interactions with
support cells, or environmental changes (e.g., nutrient levels, drugs
of abuse, stress, inﬂammation, aging, and other microenvironmental
triggers). This modulation of neuronal gene expression occurs via
transcriptional and epigenomic mechanisms, which are likely to be
adapted to accommodate the special requirements of neurons.
The ﬁeld of epigenomics has exploded in recent years with im-
proved assays, the generation of genome-wide epigenomic maps
frommultiple tissues, the identiﬁcation of a host of epigenetic regula-
tors important in numerous types of cancers, and the potential for the
development of novel epigenetic therapies. Does this explosion ex-
tend to neuroepigenomics? Fig. 1A shows the exponential increase
in the number of funded R01 grants related to epigenetics or
epigenomics from 3 neuroscience-focused National Institutes ofe), amitchen@mail.nih.gov
ena.procaccini@nih.gov
ie@nih.gov (A.C. Lossie).
ss article under the CC BY-NC-NDHealth (NIH) Institutes, indicating that many researchers are working
in this scientiﬁc space. Fig. 1B shows the increasing number of primary
publications on topics that touch upon neuroepigenetics or
neuroepigenomics, suggesting that epigenomic questions have capti-
vated the neuroscience community.
Forays into neuroepigenetics research have led to a number of
groundbreaking discoveries in substance use disorders, brain devel-
opment, neurodegeneration, intellectual disability, memory, and
even transgenerational inheritance of behavioral phenotypes. Be-
cause several reviews have discussed the role of epigenetic regulation
in the nervous system, we will brieﬂy highlight a few of the key dis-
coveries below (Bellet and Sassone-Corsi, 2010; Bennett et al.,
2014; Day and Sweatt, 2011; Dulac, 2010; Feng and Nestler, 2013;
Haggarty and Tsai, 2011; Ma, 2010; Maze et al., 2011, 2013, 2014;
Namihira et al., 2008; Nelson and Monteggia, 2011; Pena et al.,
2014; Rahn et al., 2013; Rogers et al., 2011; Sweatt, 2013; Zocchi
and Sassone-Corsi, 2010). For example, work from Eric Nestler’s
laboratory has shown that cocaine exposure leads to deﬁned changes
in histonemodiﬁcations and DNAmethylation of neuronal regulators
in the nucleus accumbens (LaPlant et al., 2010; Nestler, 2014; Renthal
et al., 2007, 2009). Investigations into autism and intellectual disabil-
ity disorders indicate that epigenetic regulators (e.g., MECP2, MBD5,
JARID1C, DNMT3A, ARID1B) play important roles in these disorders
(Jensen et al., 2005; Moretti and Zoghbi, 2006; Santen et al., 2012;
Talkowski et al., 2011; Tatton-Brown et al., 2014; Tsurusaki et al.,
2012). Several lines of evidence point to an epigenetic basis
underlyingmemory processing.Work fromDavid Sweatt’s laboratorylicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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tion and maintenance (Day and Sweatt, 2011; Guzman-Karlsson
et al., 2014; Miller et al., 2008, 2010; Zovkic et al., 2014). Marcelo
Wood and colleagues have found Brg1-associated factor chromatin
remodeling complexes to be necessary formemory and synaptic plas-
ticity (Vogel-Ciernia et al., 2013). Li-Huei Tsai and colleagues have
found that histone deacetylase (HDAC) inhibitors can effectively re-
establish access to memories after neurodegeneration (Graff et al.,
2012, 2014; Rudenko andTsai, 2014). There is even evidence that cer-
tain exposures can lead to intergenerational inheritance of behavioral
phenotypes (Byrnes et al., 2011; Dias and Ressler, 2014; Gapp et al.,
2014; Szutorisz et al., 2014; Vassoler et al., 2013).
One of the most important epigenetic discoveries in the last
several years is the identiﬁcation of TET-mediated oxidized deriva-
tives of 5-methylcytosine (5mC): 5-hydroxymethylcytosine
(5hmC), 5-formylcytosine, and 5-carboxylcytosine in mammals
(Cheng et al., 2014; Ito et al., 2011; Kriaucionis and Heintz, 2009;
Mellen et al., 2012; Rudenko and Tsai, 2014; Sun et al., 2014; Tahiliani
et al., 2009). 5-hydroxymethylcytosine is especially abundant in the
brain with up to 10-fold higher levels compared to embryonic stem
(ES) cells and other tissues. 5-hydroxymethylcytosine modiﬁcation
of DNA, initially discovered in Purkinje cells, is now known to play a
critical role in stem cell biology and has emerging roles in other cell0
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Fig. 1. (A) Increasing NIH-funded research in neuroepigenetics. Theﬁgure shows cumu-
lative number of funded R01 epigenetic/epigenomic grants from 2005 to 2013 from
3 neuroscience-focused NIH institutes: National Institute on Drug Abuse, National Insti-
tute onMental Health, andNational Institute ofNeurological Disorders andStroke. These
data were obtained by searching NIH Reporter (http://projectreporter.nih.gov/reporter.
cfm) in June 2014 for funded grants that used the terms epigenetic or epigenomic in their
abstract or speciﬁc aims. (B) Increasing numbers of nonreview publications in
neuroepigenetics. The ﬁgure shows the increasing number of nonreview publications
over time in the area of epigenetics or epigenomics in the nervous system. PubMed
(http://www.ncbi.nlm.nih.gov/pubmed) was searched in June 2014 for titles or
abstracts that mention epigen (to capture epigenetics or epigenomics) and a nervous
system term (nervous system or neuro or brain). The search was performed to capture
only nonreview publications.types and in nervous system disorders (Cheng et al., 2014;
Kriaucionis and Heintz, 2009; Mellen et al., 2012; Rudenko and Tsai,
2014; Tahiliani et al., 2009). For example, analysis in speciﬁc brain
cell types demonstrates that MeCP2, an epigenetic regulator known
for its ability to bind 5mC of inactive gene promoters, binds 5hmC
in active gene bodies in Purkinje cells, granule cells, and Bergmann
glial cells (Mellen et al., 2012). In the brain, this observation is accom-
panied by the loss of 5mC and an increase in 5hmC in the gene body
of active genes. These observations are likely to have important im-
plications in regard to gene expression and brain plasticity.
Tools and technologies for neuroscience research have improved
signiﬁcantly and will continue to improve through projects such
as Brain Research through Advancing Innovative Neurotechnologies
(BRAIN) http://www.nih.gov/science/brain/2025/index.htm.
Neuroepigenomics will no doubt be an important component of
many future discoveries in neuroscience. This review focuses on a
few of the currently available resources that neuroepigenomics re-
searchers might ﬁnd useful, including reference epigenome maps,
epigenomic assays and imaging tools, and recent key discoveries in
disease research. We will also discuss several of the current obstacles
and opportunities in neuroepigenomics research, including tools for
single-cell analysis and epigenomic manipulation, the need for addi-
tional brain cell reference epigenome maps, a deeper understanding
of the mechanisms of transgenerational epigenetic inheritance, and
the further development of epigenetic biomarkers and therapeutics.
These obstacles and opportunities will become increasingly impor-
tant as the ﬁeld of neuroepigenomics emerges from “adolescence.”
Resources and tools for neuroepigenomics
As shown in Fig. 2, the Roadmap Epigenomics Program (support-
ed by the NIH Common Fund) consists of multiple components with
different functions, including (1) development of new technologies
to improve epigenome-wide assays, advance epigenetic imaging,
and enable functional epigenetic manipulation; (2) identiﬁcation
and characterization of novel epigenetic marks; and (3) investigation
of epigenomic processes underlying human disease (Satterlee et al.,
in press). Additionally, reference epigenome maps from normal
cells and tissues were generated and uniformly processed by the
Mapping Consortium and a Data Coordination Center. These data
were deposited into NIH databases (Gene Expression Omnibus or da-
tabase of Genotypes and Phenotypes) where they can be accessed by
researchers (Bernstein et al., 2010). Most recently, a Computational
Epigenomics component was added to support secondary data anal-
ysis studies using reference epigenomemapping data and other user-
generated or public data sets to investigate important biological
questions or diseases. Overall, 83 R01, R21, or RC1 grants were
funded through the Roadmap Epigenomics Program. Below we will
discuss some of the neuroepigenomic-relevant tools and resources
generated by these researchers.
Reference epigenome maps for the nervous system
In the nucleus, genes are turned on and off via a sophisticated in-
terplay of transcriptional regulators; the consequences of this elabo-
rate dance can be monitored in part through the assay of
epigenomic features. The NIH Roadmap Epigenomics Program has
generated a comprehensive catalog of epigenomemaps for 92 distinct
normal human cells and tissues (Bernstein et al., 2010). These maps
were anticipated to stimulate a variety of hypothesis-generating stud-
ies such as (1) the identiﬁcation of tissue-speciﬁc functional genetic
elements, (2) uncovering the breadth of epigenomic plasticity during
cellular differentiation, and (3) establishing a normal reference for in-
vestigators exploring the effects of environment or disease on the
4 J.S. Satterlee et al. / Neuroepigenetics 1 (2015) 2–13epigenome (Bernstein et al., 2010; Pollock et al., 2014; Satterlee et al.,
in press).
These reference epigenomes (http://www.roadmapepigenomics.
org) are available to the research community, and prior publications
have outlined how to access and visualize the data (Chadwick, 2012;
Satterlee et al., in press). The reference data sets typically include
DNA methylation assays, chromatin immunoprecipitation followed
by sequencing for a core set of 6 post-translational histone modiﬁca-
tions, and messenger RNA (mRNA) expression analysis. In some
cases, tissues were also assayed for chromatin accessibility using
DNAse I hypersensitivity assays. As indicated in Table 1, these assays
can be used to help identify gene promoters, tissue-speciﬁc en-
hancers, or actively transcribed or repressed regions of the genome
(Rada-Iglesias et al., 2011; Guenther et al., 2007; Kimura, 2013;
Barski et al., 2007; Creyghton et al., 2010; Wagner and Carpenter,
2012; Grewal and Jia, 2007; ENCODE Project Consortium, 2012).
Table 1 shows the assays used to interrogate a variety of
neuroscience-relevant cells and tissues, including ES cells, ES-
derived cells including neural progenitor cells, induced pluripotent
stem (iPS) cells, postmortem fetal tissues (brain and spinal cord),
and postmortem adult brain (angular gyrus, anterior caudate, cingu-
late gyrus, hippocampus, inferior temporal lobe, midfrontal lobe, and
substantia nigra). The Human Epigenome Browser (http://
epigenomegateway.wustl.edu/info/) provides an Ensembl-like visu-
alization of these epigenomic data and can even display long-range
genomic interactions (Zhou et al., 2011, 2013). The Roadmap
Epigenomics Mapping Consortium has also developed a set of exper-
imental protocols, assay standards, and data quality standards to aid
researchers who wish to perform these types of assays in their own
laboratories (http://www.roadmapepigenomics.org/protocols).
Additional data sets relevant for the neuroscience community have
been generated by the International Human Epigenome Consortium
(IHEC), Encyclopedia of DNA Elements (ENCODE), MethylomeDB,
Brain Cloud, and Brainspan projects. As shown in Table 1, the IHEC is
generating similar epigenomic data sets for several additionalFig. 2. NIH Common Fund (Roadmap) Epigenomics Program components. The reference ep
and databases where scientists can obtain this information (Gene Expression Omnibus and
recently funded to support computational investigations into important biological questions or
tives endeavored to improve epigenome-wide assays, improve epigenetic imaging, and enable
and characterization of novel epigenetic marks as well as investigations into epigenomic procehuman brain samples including prefrontal cortex, glioblastoma, and
malignant glioma (http://ihec-epigenomes.org/outcomes/datasets/).
Similarly, the ENCODEproject has data for several humanpostmortem
brain regions (https://www.encodedcc.org) (Bernstein et al., 2012).
As a part of the mouse ENCODE project, epigenomic and gene expres-
sion assays have been performed on forebrain, midbrain, hindbrain,
and a number of other brain regions. MethylomeDB provides
genome-wide DNA methylation data for selected mouse and human
brain regions (http://www.neuroepigenomics.org/methylomedb/)
(Xin et al., 2012). Two projects have collected longitudinal data that
include fetal development. The Brain Cloud project showcases gene
expression and DNA methylation data for postmortem human pre-
frontal cortices from fetal development through the aging adult
(http://braincloud.jhmi.edu/) (Colantuoni et al., 2011), whereas
BrainSpan provides transcriptome data for the developing human
brain from prenatal through postnatal development (http://www.
brainspan.org/). See Table 1 for details about these selected resources
for neuroepigenomics.
These data sets can be exploited for a variety of scientiﬁc investi-
gations. For example, epigenomic data have enhanced the analysis of
Genome Wide Association Study (GWAS) (Ernst et al., 2011;
Karczewski et al., 2013; Maurano et al., 2012; Pasquali et al., 2014;
Trynka et al., 2013). In one study, researchers found that a signiﬁcant
percentage of disease-associated single nucleotide polymorphisms
fromGWAS occur in DNAse I–hypersensitive sites that are frequently
associated with transcription factor binding (Maurano et al., 2012).
This combined epigenomic and GWAS analysis can enable re-
searchers to mine GWAS data sets for relevant gene variants that
were not statistically nominated using standard analysis methods.
Aberrant gene silencing or activation could explain some of the vari-
ability in GWAS ﬁndings and underscores the value of integrating
epigenomic data with gene expression and genotype information.
Remarkably, epigenomic and GWAS analyses can also be useful for
predicting the cell types or tissues most likely to be impacted by a
human disease phenotype (Maurano et al., 2012). For human brainigenomemapping components included Mapping Centers, a Data Coordination Center,
database of Genotypes and Phenotypes). A Computational Epigenomics component was
diseases using reference epigenomemapping data. Three technology development initia-
functional epigenetic manipulation. Two additional components included identiﬁcation
sses in human disease.
5J.S. Satterlee et al. / Neuroepigenetics 1 (2015) 2–13disorders, a comprehensive set of cell type and brain region–speciﬁc
epigenomic data sets could enhance our ability to identify new gene
variants involved in disease and help corroborate or even predict
cell types or brain regions disrupted in human brain disorders.
Epigenomic assay and imaging tools
Some of the technologies developed through the NIH Roadmap
Epigenomics Program have contributed greatly to our ability to per-
form epigenetics research. For example, the MethylC-seq whole ge-
nome bisulﬁte sequencing assay developed in the Ecker laboratory
can be used to characterize methylomes, which are deﬁned as all of
the methylated and nonmethylated DNA cytosine residues in a cell
type or tissue (Lister et al., 2009). This assay was used to pioneer the
exploration of mammalian methylomes, and the publication describ-
ing it has been cited more than 1082 times as of June 2014. These re-
searchers found that a signiﬁcant fraction of DNA methylation
occurred in a non-CG context in human ES cells and later revealed im-
portant DNAmethylation differences between human ES cells and iPS
cells (Lister et al., 2009, 2011). MethylC-seq and related methylome
assays have been applied to a variety of mammalian cell and tissue
types, including the brain, by the Roadmap Mapping Consortium
(Table 1) as well as other researchers (Guo et al., 2014; Hovestadt
et al., 2014; Varley et al., 2013). For example, during mammalian
brain development, 5-methylcytosine and 5-hydroxymethylcytosine
undergo profound reconﬁguration (Lister et al., 2013). The develop-
ment or improvement of other epigenomic assays has also signiﬁcant-
ly enhanced our ability to interrogate the epigenome. For example,
padlock probes allow the interrogation of DNA methylation at
investigator-selected speciﬁc regions of the genome without the
need for expensive whole genome sequencing (Deng et al., 2009;
Diep et al., 2012), whereas nanoﬂuidic approaches have been used
to investigate the epigenomic state of single molecules (Cipriany
et al., 2010, 2012).
Epigenomic assays have been improving steadily; however, they
typically provide measurements for only a single point in time. Our
ability to observe chromatin features dynamically and in vivo has
been quite limited. Researchers in the Lomvardas and Larabell labora-
tories are using soft x-ray tomography to investigate chromatin do-
mains in mouse olfactory neurons. Each neuron expresses only 1
olfactory receptor; the remaining ones are silenced. These studies
show that reductions in lamin b receptor levels lead to the aggrega-
tion of the silenced olfactory receptors in the nuclear periphery,
whereas the active receptors lie within an active transcriptional
zone (Clowney et al., 2012). In the future, soft x-ray tomography
could be combined with a ﬂuorescence complementation strategy to
enable visualization of epigenetic regulators in vivo. Using this strate-
gy, a ﬂuorescent signal is only observed following interaction of 2 pro-
teins labeled with partial complementary ﬂuorescent domains. As
these and related approaches improve our ability to image chromatin
features in vivo (including noncoding RNAs, DNA binding proteins,
and modiﬁed histones), it is hoped that neuroscientists will be able
to use these tools to better investigate how chromatin territories are
associated with gene regulation in the nervous system.
A critical consideration for brain researchers is our almost com-
plete inability to obtain brain specimens from living humans for
epigenomic analysis. Each mammalian cell type is believed to exhibit
a distinct epigenome; thus, interrogation of the brain epigenomes of
speciﬁc cell types may be essential for disease diagnosis. Some re-
searchers funded through the Roadmap Epigenomic Program have
been exploring methods for in vivo imaging of epigenetic enzymes
to begin to overcome this obstacle. Speciﬁcally, these researchers
are developing positron emission tomography (PET) radiotracers
for class I and class III HDACs (Schroeder et al., 2013; Wang et al.,2013; Yeh et al., 2013). Development and pharmacokinetic optimiza-
tion of these in vivo brain permeable PET ligands that monitor HDAC
levels or activity in humans could improve accuracy of disease diag-
nosis, enable monitoring of the efﬁcacy of epigenetic therapeutics,
or enhance our ability to explore the effects of environmental factors
such as psychosocial stress or substance abuse.
Disease investigations
Historically, cancer researchers have been the most strenuous
pursuers of epigenetic studies. However, many scientists have won-
dered about the potential role of epigenetic regulation in other dis-
eases and chronic conditions including those that impact the
nervous system. To encourage work in this area, the Roadmap
Epigenomics Program supported research projects that investigated
potential epigenetic changes that underlie a number of diseases in-
cluding autism, Alzheimer’s disease (AD), schizophrenia, bipolar dis-
order, and substance use disorders. Some of the publications
associated with these investigations can be found at the following
Web site: http://www.roadmapepigenomics.org/publications.
Of particular interest are 2 recent epigenome-wide association
studies that proﬁle alterations in CpG methylation in postmortem
brain regions of patients with AD. The investigators independently
converged on several loci including CpG dinucleotides near ANK1,
RPL13, CDH23, and RHBDF2 (De Jager et al., 2014; Lord and Cruchaga,
2014; Lunnon et al., 2014). Interestingly, calculations by one group
suggested that the 71 CpG variants they identiﬁed explained 28.7%
of the variance in neuritic amyloid plaque burden, whereas all
known AD gene variants from GWAS studies explained only 13.9%
of the variance (De Jager et al., 2014; Lord and Cruchaga, 2014).
Thus, epigenomic studies can reveal new candidate loci involved in
brain diseases and suggest that DNA methylation may play a role in
the onset or progression of AD.
Technology, tool, and research needs for neuroepigenomics
Although the ﬁeld of neuroepigenomics has made great strides, it
is clear that even greater progress has been hampered by speciﬁc ob-
stacles that must be overcome. Brieﬂy, we will describe some of the
technology needs for neuroepigenomics, such as tools for epigenomic
manipulation and robust single-cell assays. Similarly, resource
and data set needs in neuroepigenomics include: expanding
neuroepigenomic data sets, exploration of human neuroepigenomics
using imaging technologies and postmortem brain resources, as well
as the exploration and development of neuroepigenomic surrogates
and biomarkers. Finally, there are some very exciting opportunities
in neuroepigenomics research that should not be overlooked includ-
ing exploration of the 4-dimensional (4D) structure of neuronal ge-
nomes, somatic mosaicism in neuronal cells, environmental
epigenomics, investigation of mechanisms of intergenerational inher-
itance of behavioral phenotypes, and further development of epige-
netic neurotherapeutics.
Technology needs for neuroepigenomics
Tools for cell-type–speciﬁc, locus-speciﬁc, and temporal manipulation of
neuronal epigenomes
In the nervous system, optogenetic and chemogenetic strategies
have been instrumental in enabling neuroscientists to explore ques-
tions regarding neuronal function (Chow et al., 2012; Dong et al.,
2010; Fenno et al., 2011; Wess et al., 2013). However, long-term
changes in neuronal function are associatedwith concomitant chang-
es in gene expression via transcription factor and epigenomic
Table 1
Selected neuroepigenomics data resources.
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changes in the nervous system via manipulation of the epigenome
and the associated expression of genes has lagged in comparison;
most strategies use small-molecule modulators (e.g., HDAC inhibi-
tors) or RNA silencing methods. These approaches provide limited
temporal control and impact many cell types and genomic loci. The
ability to conduct spatiotemporal manipulation in vivo would enable
researchers to probe the effects of locus-speciﬁc changes to the epige-
nome in neuronal or glial cells in a reversible manner. Some re-
searchers are already making important strides in this direction. For
example, Feng Zhang and colleagues have developed ﬁrst-generation
genetic tools called LITES (light-inducible transcriptional effectors)
that enable researchers to optically control transcriptional and epige-
netic states (Konermann et al., 2013).
To address this critical technology gap, the Roadmap Epigenomics
Program is supporting the development of a variety of robust tools
and technologies in this area. These include manipulating the epige-
nome at speciﬁc loci using genome editing technologies (e.g., tran-
scription activator-like effectors (TALES), clustered regularly
interspaced short palindromic repeats (CRISPR)), temporally regulat-
ing the epigenome via opto-epigenetic or chemo-epigenetic strate-
gies, and exploiting available genetic tools to achieve cell-type
speciﬁcity in key model organisms. It will be of great interest to see
what fundamental questions in neuronal gene regulation can be an-
swered using these platforms.
Single-cell analyses
During normal growth and differentiation, cells must tightly con-
trol if, when, and where gene expression occurs. Epigenetic marks
are critical in ensuring that the correct gene expression patterns are
maintained and transmitted to the next generation of cells. Each
type of cell displays a distinct epigenomic proﬁle that reﬂects its
past experiences and developmental potential (Gifford et al., 2013;
Zhu et al., 2013). This epigenetic proﬁle is read by the transcriptional
machinery, creating a unique gene expression signature. Current tech-
nologies permit epigenetic marks to be studied in extracts from large
populations of cells, yet epigenetic gene regulation occurs within sin-
gle living cells (Wills et al., 2013). Distinct microenvironments within
cellular niches likely inﬂuence the molecular and cellular phenotypes
of different cell types. Induced pluripotent stem (iPS) cells provide a
striking example of this cellular diversity, because only some of the
precursor cells have the necessary plasticity to de-differentiate into a
pluripotent state (Smith et al., 2010). This ability to transform from
a differentiated state to an iPS cell may reﬂect the individual
epigenomes of these cells. Unfortunately, current technologies do
not permit analysis of a given epigenomic modiﬁcation in a single
cell at a global scale. This challenge is especially acute in learning
and memory studies, where epigenomic changes may occur in re-
sponse to neural activity (Zovkic et al., 2013). Although improve-
ments have allowed glimpses into the DNA methylation and gene
expression proﬁles at the single-cell level, more work must be done
to enable assay of histonemodiﬁcations and other chromatin features
at the single-cell level (Hayashi-Takanaka et al., 2011; Iourov et al.,This table highlights resources generated by several large-scale projects of relevance to neu
left, whereas epigenomicmodiﬁcations, putative functions, and assay type are shown at the
erated by the NIH Roadmap Epigenomics Program (www.roadmapepigenetics.org) (Bernste
search/cell-types) as well as the ENCODE project (https://www.encodedcc.org) (Bernstein e
IHEC members, so the IHEC data sets shown in this table were generated by the other
methylomedb/), Brain Cloud (http://braincloud.jhmi.edu/), and BrainSpan (http://www.b
et al., 2012). A blue square indicates the data are currently available, a green square indica
given assay for this cell or tissue type. Histone modiﬁcations (e.g., H3K36me3) were assaye
Key: DNase I HS, DNase I hypersensitivity assay; MeDIP, methylated DNA immunoprecipita
ing;MRE, methylation-sensitive restriction enzyme sequencing; RRBS, reduced representati2012; Patel et al., 2014; Shalek et al., 2014; Smallwood et al., 2014).
There is great hope that the Common Fund Single Cell Analysis pro-
gram (https://commonfund.nih.gov/Singlecell) will facilitate the
development of platforms with the capability of studying the
epigenomes and gene expression proﬁles of individual cells.
Resource and data set needs for neuroepigenomics
Expanded neuroepigenomic data sets
Although the Roadmap Epigenomics Program and other projects
have generated valuable epigenomic data sets, systematic efforts to
apply molecular phenotyping strategies to the nervous system are
lacking. A comprehensive atlas of molecular phenotypes that spans
a wide variety of brain regions, brain cell types, and developmental
stages for both human and mouse is crucial for understanding the
molecular etiology and ontology of neurological diseases. Key molec-
ular phenotypes should encompass chromatin features (e.g., histone
or DNA modiﬁcations), transcription factor binding sites, and mRNA
or binding sites, and RNA expression whenever possible. The histone
variant H2A.Z was recently shown to play a role in memory consoli-
dation, suggesting that histone variants would be an important mo-
lecular feature to assay (Zovkic et al., 2014). Secondary molecular
phenotypes that could be assayed include modiﬁed RNAs, circular
RNAs, and higher-order chromatin structure. Ideally, thesemolecular
phenotypes will be connected whenever possible to brain cell mor-
phology, connectivity, and electrophysiological measures. In addition
to helping elucidate the ontology of disease, molecular phenotypes
will aid in the interpretation of GWAS and other data sets that inves-
tigate psychiatric diseases, as well as help to delineate candidate cell-
type–speciﬁc molecular targets for the development of small-mole-
cule therapeutics.
Human brain disease epigenomics: postmortem and imaging resources
Investigation of the human brain epigenome is a necessary step to
understanding long-term changes in gene regulation and gene ex-
pression that may be associated with neurodevelopmental or neuro-
psychiatric disorders. It is also important to determine the extent to
which the molecular pathways that regulate brain phenotypes in ro-
dent and non-human primate models are recapitulated in humans.
For studies exploring the mechanisms of disease processes, it is of
critical importance to study the epigenomic changes that occur in
the tissue and cell types speciﬁcally associated with that disease.
Yet unlike diseases involving blood or skin, epigenomic assay of the
human brain is particularly problematic. It is uncommon to obtain
fresh surgical specimens, and, even when available, these brain sam-
ples are typically associated with a pre-existing disease state.
Post-mortem human studies are therefore essential for investigat-
ing epigenomic changes associated with brain diseases. However,
alterations occurring at or near the time of death (e.g., changes in ox-
ygen levels or brain pH) can negatively impact the stability and levels
of molecular brain phenotypes. Minimization of the interval between
death and brain collection is essential for maximal preservation ofroepigenomics researchers as of September 2014. Cell or tissue types are shown on the
top (see text for further details). The upper section of the table describes resources gen-
in et al., 2010). This is followed by data from the IHEC (http://ihec-epigenomes.org/re-
t al., 2012). Please note that the Roadmap Epigenomics Program and ENCODE are both
IHEC members. Data from the MethylomeDB (http://www.neuroepigenomics.org/
rainspan.org) projects are also shown (Colantuoni et al., 2011; Miller et al., 2014; Xin
tes assays are in progress, whereas a white square indicates no data are available for a
d by chromatin immunoprecipitation followed by sequencing.
tion sequencing;, Methyl-MAPS, methylation mapping analysis by paired-end sequenc-
on bisulﬁte sequencing; smRNA-seq, small RNA sequencing; TSS, transcription start site.
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tion marks can be fairly well preserved in postmortem brain samples,
and mRNA proﬁling has been performed successfully (Colantuoni
et al., 2011; Ernst et al., 2008; Kang et al., 2011; Twine et al., 2011).
However, histone modiﬁcations and other chromatin features may
be less stable, and some classes or subsets of RNAsmay have differen-
tial sensitivity to the postmortem interval (Barrachina et al., 2012).
Animal studies have been used to examine alterations in mRNA ex-
pression associated with the interval between postdissection and tis-
sue preservation. Depending on the length of the interval, clear gene
expression signatures emerge both temporally and functionally (e.g.,
hypoxia inducible genes, heat shock proteins, stress-response genes
etc.) (Catts et al., 2005; Durrenberger et al., 2010; Sanoudou et al.,
2004; Trotter et al., 2002; Zhao et al., 2006). To better address the ex-
tent to which fresh and postmortem human tissues differ, freshly
resected normal or diseased tissue with minimal time to preservation
can be compared to more widely available postmortem human brain
tissue. Comparisons of gene expression proﬁles for these 2 conditions
are currently under way for human non-brain tissue in the Common
Fund Genes, Tissue, and Expression (GTEx) program (http://www.
gtexportal.org/home/). One confounding issue is the lack of appropri-
ate controls with human postmortem research due to unique geno-
types and environmental exposures. However, postmortem brain
studies have been successful for helping understand human brain
function and disorders such as autism and AD (Colantuoni et al.,
2011; Davies et al., 2012; De Jager et al., 2014; Kang et al., 2011;
Lunnon et al., 2014; Mill et al., 2008; Twine et al., 2011; Voineagu
et al., 2011).
An alternative possibility for exploring the human brain epige-
nome is the use of in vivo imaging approaches. As described earli-
er, PET ligands can be used to measure the amount and activity of
certain HDACs. Although this does not reveal epigenomic informa-
tion at the single-gene level or for an individual cell type, these ap-
proaches may have value for disease diagnosis and measurement
of therapeutic efﬁcacy. The development of in vivo molecular im-
aging approaches to monitor a greater variety of epigenomic
readers, writers, and erasers as well as approaches that enable
more reﬁned measurement of epigenomic features would revolu-
tionize neuroscience research.
Neuroepigenomic surrogates and biomarkers
Given our inability to obtain human brain samples from living pa-
tients, another approach of great potential clinical utility is to identify
robust peripheral indicators that closely reﬂect both the phenotypic
and epigenomic changes identiﬁed in disease-relevant brain cells.
These peripheral indicators could include accessible cell types such
as blood cells, skin, buccal samples, olfactory epithelia, or even body
ﬂuids. Both animal and human studies could be used to advance
our knowledge in this area. Animal studies would enable experimen-
tal control of genotype and environment and would provide a more
detailed understanding of how epigenomic events in the brain are
correlated with molecular phenotypes in more accessible cell types.
Parallel human experiments could be carried out using postmortem
brain and peripheral tissues from the same donor. The Common
Fund Genes, Tissue, Expression (GTEx) program (http://www.
gtexportal.org/home/) will in part address the latter scientiﬁc ques-
tion, because one goal of this program is to capture genotype and
RNA-seq information for 50 tissues from each individual donor.
When the GTEx program is completed, it is expected that data for
900 individual donorswill be available. Epigenomic and othermolec-
ular phenotype assays will be added to the GTEx data sets for some
tissues, whichmay help to identify the surrogate tissues most salient
for brain investigations (Lonsdale et al., 2013). However, a surrogatetissue strategymay not yield useful biomarkers for all neurological dis-
orders. A recent AD epigenome-wide association study reports that the
DNA methylation state of surrogate tissues (cerebellum and whole
blood) does not recapitulate disease-relevant DNA methylation differ-
ences in brain tissues impacted by AD (superior temporal gyrus and
prefrontal cortex) (Lunnon et al., 2014).
Body ﬂuids are another potential source for generation of informa-
tive biomarkers. Extracellular vesicles and proteins associated with
extracellular RNAs, exRNAs, appear to move through the body and
act in ways analogous to the endocrine system (Christianson et al.,
2014; Lai and Breakeﬁeld, 2012; Yang et al., 2011). The best current
candidates to test for extracellular RNA content include cerebral spi-
nal ﬂuid (CSF) and blood serum, although other bodily ﬂuids could
provide additional informative biomarkers (Revenfeld et al., 2014;
Saman et al., 2012). Studies aimed at generatingmethods to purify ex-
tracellular vesicles derived solely from the brain could, theoretically,
prove an exceptionally useful source of biomarkers for brain disorders.
Additional opportunities in neuroepigenomic research
The neuronal genome: 4D structure
Evidence from imaging, as well as genome conformation assays, in-
dicates that cellular genomes have complex and dynamic 3-dimen-
sional structures (Clowney et al., 2012; Fullwood et al., 2009;
Lieberman-Aiden et al., 2009; Mitchell et al., 2014). Although our
knowledge of the structure of neuronal or glial genomes is poorly un-
derstood, recent studies demonstrate that olfactory neurons display a
complex genomic architecture that differs between olfactory neuron
types depending upon the gene expression status of individual olfacto-
ry receptors (Clowney et al., 2012). Furthermore, adenosine triphos-
phate–dependent chromatin remodeling proteins such as Brg1-
associated factor 53b (BAF53b) have neurodevelopmental, synaptic
plasticity, and memory functions, suggesting that genome conforma-
tion plays an important role in the nervous system (Staahl and
Crabtree, 2013; Vogel-Ciernia et al., 2013; Yoo et al., 2009). However,
a systematic investigation of the 4D structure of the genome conforma-
tion of distinct neuronal cell types is needed to understand the extent
of the relationship between genome conformation and neuronal func-
tion. The recently launched Common Fund 4D-Nucleome programwill
begin to address some of the scientiﬁc questions in this area (http://
commonfund.nih.gov/4Dnucleome/index). Studies aimed at gaining a
deeper understanding of how transcription factor binding, epigenomic
modiﬁcations, and 4D nuclear architecture correlate with gene expres-
sion would yield important insights into the complexities and dynam-
ics of gene regulation in normal tissues and during disease processes.
Brain somatic mosaicism and epigenomic regulation
It is often assumed that the genomes of all of our cells are identi-
cal. However, this is always the case. For example each haploid germ
cell contains a distinct genome, whereas every B cell and T cell un-
dergoes a unique recombination event that generates a repertoire
of immune cells that are poised to attack different types of antigens
(Alt and Baltimore, 1982; Roth et al., 1992). It is becoming increasing-
ly clear that as cells in the nervous system differentiate, theymay un-
dergo genomic rearrangements or acquire copy number or other
structural variations, which ultimately can lead to signiﬁcant levels
of somatic mosaicism in the brain. For example, Jerold Chun and col-
leagues demonstrated that distinct cells from the nervous system dif-
fer dramatically in their complement of chromosomes (Bushman and
Chun, 2013; Rehen et al., 2005; Westra et al., 2010). Furthermore, L1
retrotransposons can become active, jumping into different chromo-
somal locations within the brain (Erwin et al., 2014; Muotri et al.,
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epigenomic regulation modulates transposon activity (Creasey et al.,
2014; Lorenz et al., 2012). Interestingly, MeCP2, which is mutated
in patients with Rett syndrome (an autism spectrum disorder), can
regulate L1 transposition (Amir et al., 1999; Muotri et al., 2010).
MeCP2 is known for its role in regulating epigenetic processes; it
binds 5mC residues, as well as the oxidized derivative, 5hmC. 5-
hydroxymethylcytosine levels are higher in the brain than any other
tissue (Kriaucionis and Heintz, 2009), and it would be intriguing to
understand the potential roles that 5mC and 5hmC may play in
retrotransposon activation.
In addition to somatic mosaicism on the genomic level, females
display partial somatic mosaicism on an epigenetic level due to
X-chromosome inactivation. X-inactivation is apparently random
and leads to clustering of daughter cells; some will inactivate the
maternal X chromosome, whereas others will inactivate the paternal
X chromosome. DNA methylation, histone code changes, and ex-
pression of ncRNAs mediate this process (Gendrel and Heard,
2014). X-inactivation can contribute to disease phenotypes in
Rett syndrome (Braunschweig et al., 2004) and other neurobehav-
ioral disorders (Lasalle and Yasui, 2009), where the males are
often more highly affected than the females. In addition, regions
subject to genomic imprinting also display localized somatic mosai-
cism at the epigenetic level, as the epigenotypes on the maternal al-
leles differ from the paternal alleles. Mistakes in this process lead to
several imprinted disorders, including Prader-Willi syndrome and
Angelman syndrome (Horsthemke and Wagstaff, 2008; Reis et al.,
1994). Individuals affected by Prader-Willi syndrome exhibit spe-
ciﬁc behavioral phenotypes that include hyperphagia and obses-
sive-compulsive disorder (Saitoh et al., 1997), whereas those
affected by Angelman syndrome display severe developmental
delay, an easily excitable personality with an inappropriately
happy affect, profound movement and balance deﬁcits, as well as
seizures (Lossie et al., 2001). One important area for future re-
search is to explore the extent to which somatic mosaicism, at
the genomic and epigenomic levels, occurs in the brain and whether
or not it underlies neurodevelopmental, neuropsychiatric, or sub-
stance abuse disorders.Environmental epigenomics investigations
Environmental exposures such as prenatal environment, early
childhood or adult trauma, psychiatric medications, or exposure to
substances of abuse are associated with epigenomic alterations in
particular brain cell types (McGowan et al., 2009; Miller et al., 2010;
Nestler, 2014; Pena et al., 2014; Rutten and Mill, 2009; Satterlee,
2013; Toffoli et al., 2014; Zhang et al., 2013). Although several studies
have documented these changes, they have not been systematically
investigated. Inmost cases, it is unclear how long these presumed en-
vironmental epimutations perdure andwhatmolecular pathways are
involved in maintaining or reversing these changes (Berger et al.,
2009; Guerrero-Bosagna et al., 2013; Robison and Nestler, 2011;
Zhang et al., 2013). One approach to address these questions would
be to perform tightly controlled, systematic experiments inwhich ge-
netically identical animals are quantitatively exposed to environmen-
tal stressors, such as psychosocial stress or substances of abuse, and
then phenotyped for a suite of epigenomic brain features at different
time points. These studies would determine the long-term plasticity
and persistence (days, weeks, months) of brain epigenome changes
and enable researchers to begin to functionally characterize the
biological processes involved in formation, maintenance, or era-
sure of brain epigenome features resulting from environmental
exposures.Mechanisms of intergenerational inheritance
There is evidence that exposure to certain chemical toxins, social
environments, or nutrient levels can, in some cases, lead to persis-
tence of particular phenotypes in subsequent generations. These phe-
notypes appear to be transmittedwithout an apparent DNAmutation
and can be transmitted even when subsequent generations have
not been exposed to the environmental factor (Carone et al., 2010;
Champagne, 2008; Crews et al., 2012; Skinner et al., 2008; Weaver
et al., 2004; Youngson andWhitelaw, 2008). For example, endocrine
disruptor (bisphenol A) exposure can lead to behavioral effects on so-
cial recognition in subsequent generations (Rissman and Adli, 2014).
Work from Chris Pierce and colleagues showed that male rats that
self-administered cocaine had sons, but not daughters, that were re-
sistant to the acquisition of cocaine self-administration and that this
phenotype was correlated with Bdnf promoter histone-3 acetylation
in sperm from cocaine-exposed fathers (Vassoler and Sadri-Vakili,
2014; Vassoler et al., 2013). Exposure to tetrahydrocannabinol
(THC), morphine, nicotine, or methamphetamine also appears to im-
pact phenotypes in subsequent generations (e.g., heroin seeking,
anxiety), although the mechanisms by which this occurs remain to
be elucidated (Byrnes et al., 2011; Itzhak et al., 2014; Rehan et al.,
2013; Szutorisz et al., 2014; Zhu et al., 2014). Chronic stress exposure
can lead to increased anxiety and other behavioral phenotypes in
subsequent generations (Saavedra-Rodriguez and Feig, 2013),
whereas early life trauma in mice impacts metabolic and behavioral
phenotypes in the next generation and may be transmitted through
sperm RNAs (Gapp et al., 2014). There has even been a report that
a parental olfactory experience (fear conditioning paired with
the odorant acetophenone) is associated with increased DNAmethyl-
ation of the acetophenone odorant receptor in sperm. The resulting
progeny exhibited increased sensitivity to acetophenone (Dias and
Ressler, 2014).
Future studies aimed at validating claims of intergenerational in-
heritance are critical to ensure that any reported ﬁndings are robust
and reproducible in different laboratories. It will also be crucial to
identify the molecular mechanisms by which changes or risk factors
are transmitted to and manifested in subsequent generations. It is
often hypothesized that germline transmission of epigenetic features
accounts for the persistence of some phenotypes over multiple gen-
erations, so it will be important to investigate the association of
germline epigenetic modiﬁcations (and any RNAs that might inﬂu-
ence these modiﬁcations) with offspring phenotype. It will also be
critical to explore alternate hypotheses, including neurobehavioral
or societal transmission or transmission through infectious agents
such as viruses or theparentalmicrobiome (Youngson andWhitelaw,
2008). Despite these caveats, this area of research has great relevance
to disease prevention, because knowledge that a particular environ-
mental exposure could lead to phenotypes in subsequent generations
would have profound public health implications.
Epigenetic neurotherapeutics
If a disease is caused by the presence of a particular gene variant
or mutation, then gene therapy approaches may ultimately be neces-
sary to correct the disorder. However, epigenetic changes are inher-
ently more plastic than DNA-based mutations and thus should be
more readily impacted by small-molecule therapeutics (Haberland
et al., 2009; Haggarty and Tsai, 2011). We will brieﬂy touch on 2
areas of epigenetic neurotherapeutic investigation: HDAC inhibitors
and histone acetylation readers such as BRD4. Histone deacetylase in-
hibitors (HDACis) have been used to treat T-cell lymphoma aswell as
bipolar disorder, migraines, and seizures (Bialer and Yagen, 2007;
Mack, 2006; Sharma et al., 2010). In animal models, HDACis can
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model (Fischer et al., 2007; Kilgore et al., 2010). For substance
abuse, prolonged inhibition of class I HDACs with MS-275 blocks co-
caine locomotor sensitization (Kennedy et al., 2013). The HDAC in-
hibitor sodium butyrate has been shown by Marcelo Wood and
colleagues to facilitate extinction of cocaine-associated cues
(Malvaez et al., 2010), suggesting that HDACis or perhaps other epi-
genetic therapeutics could be particularly efﬁcacious if used in con-
cert with behavioral therapies.
One limitation ofHDACis is that they are pleiotropic and can impact
many different cells and genetic loci. It is known that certain epigenetic
“reader” proteins can bind to a subset of histone modiﬁcations. Thus,
researchers targeted BRD4, which can bind to a subset of acetylated
lysines, in an attempt to generate therapeutics with more speciﬁcity
than HDACis (Dey et al., 2003). JQ1, a small-molecule inhibitor of
BRD4, has promise as a potential treatment for acutemyeloid leukemia
(AML) (Filippakopoulos et al., 2010; Zuber et al., 2011). Researchers
are also beginning to target histone methylation enzymes as well as
other epigenetic “readers, writers, and erasers” to treat a variety of dis-
eases including nervous system disorders (Fiskus et al., 2009; Grant,
2009; Hamada et al., 2010). It would be of great value to systematically
develop small-molecule modulators of epigenetic readers, writers, and
erasers to (1) to serve as chemical probes to investigate the functions
of these enzymes, (2) for development into ligands for in vivo imaging
studies, and (3) as potential lead compounds for future therapeutic de-
velopment (Arrowsmith et al., 2012). Somework in this area is currently
being pursued by the Structural Genomics Consortium http://www.
thesgc.org/epigenetics.
Summary
As the ﬁeld of neuroepigenomics matures, it is likely to produce
revolutionary new insights into the regulation of gene expression in
neurodevelopmental and neuroplastic processes in cells that can per-
sist for decades. It will also likely yield new and perhaps paradigm-
shifting opportunities for the diagnosis, treatment, and prevention
of diseases of the nervous system. In this review, we described a
few of the tools and technologies available to neuroepigenomics re-
searchers currently, including reference epigenomemaps for nervous
system cells and tissues, improved epigenomic assays, improved
ways to monitor epigenetic enzymes and changes in vivo, and a
deeper understanding of epigenetic mechanisms in nervous system
disorders.
We have also delineated some of the obstacles and opportunities
in this area including: improved tools for manipulating epigenetic
processes, additional reference epigenomes for the nervous system,
improved technologies for single-cell analyses, validation of animal
epigenetic studies using human postmortem tissue, investigation
into the potential of surrogate tissues and body ﬂuids as biomarkers,
and exploration of the 4-D chromatin structure of nervous system–
relevant cell types. Another important area for future work is to bet-
ter understand how acute or chronic environmental exposures (e.g.,
early life stress, drugs of abuse, environmental toxins, diet, inﬂamma-
tion, aging) impact the brain epigenome both somatically (including
the somatic genome) as well as in subsequent generations.
There are 3 additional gaps and opportunities in neuroepigenomics
that should be mentioned brieﬂy. The ﬁrst is that the computational
needs for neuroepigenomic research are challenging, and it will be im-
portant to develop user-friendly computational tools to enable re-
searchers to mine and exploit epigenomic information effectively.
Secondly, the typical graduate or postdoctoral training program for
neuroscientists differs greatly from that of epigenomicists. The devel-
opment of explicit training programs in neuroepigenomics would
help researchers be able to move more seamlessly between these 2scientiﬁc “worlds” and better train the next generation of
neuroepigenomicists. Finally, as neuroepigenomic tools and resources
improve, it is essential that individual researchers continue to initiate
cutting-edge explorations into the epigenetic mechanisms of nervous
system disorders. Without an understanding of these mechanisms at
a deep level, it will be impossible to improve the prevention, diagnosis,
and treatment of nervous system disorders due to epigenetic
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